Objectives: The aim of this study was to investigate the presence of VEB enzymes among Pseudomonas spp. referred to the UK's national reference laboratory and with phenotypic evidence of extended-spectrum b-lactamase (ESBL) production.
Introduction
The rise to dominance of CTX-M-type extended-spectrum b-lactamases (ESBLs) among members of the Enterobacteriaceae, particularly Escherichia coli, is one of the most dramatic shifts in resistance epidemiology of the early 21st century, 1, 2 supplementing the problems already caused by TEM-and SHV-derived ESBLs. In addition, a variety of 'minor' class A ESBLs have been described, 3 with the VEB enzymes representing an increasingly seen group. 3 VEB-1 enzyme was first characterized in an E. coli isolate from Vietnam in 1996, with four further sequence variants since detected in widely scattered countries, 
Materials and methods

Bacterial isolates
Antibiograms were reviewed for all isolates of Pseudomonas spp. referred to ARMRL from November 2003 to November 2007. These had been determined by agar dilution methodology. MICs were interpreted using harmonized European Committee for Antimicrobial Susceptibility Testing (EUCAST)/BSAC (v.6) breakpoints. Isolates were suspected to be ESBL producers if they showed a 4-fold reduction in ceftazidime MIC in the presence of 4 mg/L clavulanate. These isolates were recovered from storage, either at 2708C or at room temperature, for molecular investigation.
Molecular investigations
Isolates were screened by PCR for bla VEB alleles with primers VEBcas-F and VEBcas-B. 5 In addition, bla MBL alleles (encoding enzymes of the IMP, VIM, SPM, GIM and SIM groups) were sought by multiplex PCR, as described previously, 6 in isolates that also showed positive imipenem/EDTA synergy tests. Selected PCR products were sequenced using dye-terminator chemistry on a CEQ8000 Genetic Analyser (Beckman Coulter, High Wycombe, UK). Sequences were compared and aligned with reference sequences using BLAST (http://blast.ncbi.nlm.nih.gov/Blast.cgi) and CLUSTAL W (http://www.ebi.ac.uk/clustalw).
PFGE of SpeI-digested genomic DNA was employed to examine the relatedness of selected isolates, with BioNumerics software (Applied Maths, Sint-Martens-Latem, Belgium) used to determine relatedness between isolates.
Results and discussion
MIC analysis and bla VEB screening
Ceftazidime and ceftazidime/clavulanic acid MICs were reviewed for 1338 Pseudomonas spp. isolates referred during the 4 year period. Almost half (630, 47%) were resistant to ceftazidime (MIC . 8 mg/L), which emphasizes the bias towards resistance among isolates submitted to the reference laboratory. For comparison, the BSAC bacteraemia surveillance programme detected ceftazidime resistance in only 1.5% of the Pseudomonas spp. isolates tested during 2006 (http://www. bsacsurv.org/mrsweb/bacteraemia).
Clavulanic acid reduced the ceftazidime MICs for 49 (3.7%) isolates by 4-fold, and these were considered to be potential ESBL producers; all were highly resistant to ceftazidime (MICs 64 mg/L). Forty of these potential ESBL producers were recovered for molecular testing, and a bla VEB allele was detected in 32 (80%) of these, referred from 12 UK hospitals and from 1 in India. All of the VEB ESBL-producing isolates were confirmed to be P. aeruginosa.
Recognition of a hospital outbreak: co-production of VEB ESBL and VIM metallo-carbapenemase Of the 32 P. aeruginosa isolates with VEB ESBLs, 15 were referred from one UK centre (hospital A). These isolates had been recovered from patients on an intensive care unit and were referred in 2003 (1 isolate), 2006 (3 isolates) and 2007 (11 isolates). All belonged to serotype O15 and represented a single PFGEdefined strain (Figure 1 ). These isolates were multiresistant to carbapenems and other b-lactams, aminoglycosides and ciprofloxacin, but remained susceptible to colistin (Table 1) . They showed marked synergy between imipenem and EDTA (Table 1) and were positive for a bla VIM allele in addition to bla VEB . Sequencing of the PCR products from a representative of this strain identified bla VEB-1a and bla VIM-10 . The bla VEB-1a allele, which was originally associated with India, 7 encodes classic VEB-1 ESBL, but has an amino acid substitution in the signal peptide. 8 The VIM-10 metallo-carbapenemase is a variant that was originally identified in the UK (GenBank no. AY524989).
A review of records identified the likely 'index case' in hospital A's outbreak. This patient had been transferred to the UK in May 2000 from a hospital in India. A P. aeruginosa isolate from this patient was subsequently recovered from storage and referred for testing. It also belonged to serotype O15, was indistinguishable from the outbreak strain by PFGE ( Figure 1 ) and was positive for bla VEB . However, it lacked bla VIM and was susceptible to carbapenems (Table 1) .
Isolates from other hospitals
Two serotype O15 P. aeruginosa isolates from other UK hospitals clustered by PFGE with the strain from hospital A (Figure 1) . One of these, from hospital B, co-produced VEB and VIM enzymes and was linked with transfer of a patient from hospital A; the other, from hospital C, produced VEB enzyme only. The latter patient had been repatriated to the UK from Thailand in 2007 and had no known links with hospital A or B.
Only one other P. aeruginosa isolate co-producing both VEB and VIM b-lactamases was detected (from hospital D). It represented a distinct strain (Figure 1) , and a second isolate of this strain (from the same patient) produced only VEB ESBL. The remaining isolates, from eight UK laboratories and one in India, had bla VEB alone, and there was no evidence of strain spread between patients or centres.
In summary, although VEB ESBLs have not been reported previously in the UK, they proved to be the predominant ESBLs among Pseudomonas spp., which showed clear phenotypic evidence of ESBL production, present in 80% (32/40) of such isolates. However, bla VEB alleles were not detected in eight potential ESBL-producing Pseudomonas isolates, six of which showed 16-fold reduction of ceftazidime MICs by 4 mg/L clavulanate. Further work is required to define the ESBL genes responsible for these phenotypes.
We have demonstrated that VEB ESBLs are widespread in the UK, with producers referred from 12 different bacteriology laboratories. Worryingly, VEB ESBLs were found to co-exist with VIM metallo-carbapenemases in two strains of P. aeruginosa, and we identified one such strain that had caused a prolonged hospital outbreak. In this case, molecular data supported a scenario, in which (i) an O15 strain of P. aeruginosa producing VEB-1 ESBL was imported from India in 2000 to hospital A where (ii) it acquired VIM-10 metallo-carbapenemase from an unknown source and then spread to cause the outbreak. Our investigation further suggested that this serotype O15, VEB-positive P. aeruginosa strain may be widespread in the Far East, as a second representative (VIM-negative) was imported into the UK in 2007 from Thailand.
Unless molecular screening is applied to all ceftazidimeresistant isolates, the incidence of VEB and other ESBLs will be underestimated in Pseudomonas spp., because ESBL phenotypes can be masked by the genus' other b-lactam resistance mechanisms. However, such screening is an unrealistic proposition even in reference laboratories. Fortunately, the presence of ESBLs in Pseudomonas spp. rarely causes specific therapeutic dilemmas, and the genus seems not to be a major reservoir of ESBL genes for members of the Enterobacteriaceae, where CTX-M-type enzymes dominate. companies. None of these poses a conflict of interest with this work. Other authors: none to declare.
